Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs

Abstract Introduction This open-label study evaluated the immunogenicity, safety, and efficacy of sarilumab monotherapy in patients with active, moderate-to-severe rheumatoid arthritis (RA) and inadequate response or intolerance to prior conventional synthetic disease-modifying antirheumatic drugs....

Descripció completa

Dades bibliogràfiques

Autors principals:	Alvin F. Wells, Janie Parrino, Erin K. Mangan, Anne Paccaly, Yong Lin, Christine Xu, Chunpeng Fan, Neil M. H. Graham, Hubert van Hoogstraten, Albert Torri
Format:	Artigo
Idioma:	Inglês
Publicat:	Adis, Springer Healthcare 2019-05-01
Col·lecció:	Rheumatology and Therapy
Matèries:	Arthritis Biological DMARDs Rheumatoid arthritis
Accés en línia:	http://link.springer.com/article/10.1007/s40744-019-0157-3
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!